Proven MedTech Projects

How Fruh and a lead­ing US spine solu­tion provider brought a Class 3 implant through FDA sub­mis­sion and into pro­duc­tion, right first time.

Chal­lenge

A Unit­ed States medtech spine man­u­fac­tur­er need­ed to bring a Class 3 spinal implant through FDA review and into pro­duc­tion with­in twelve months, prefer­ably with­out mul­ti­ple ques­tion loops. For a device of this risk clas­si­fi­ca­tion, approval depends heav­i­ly on the qual­i­ty, com­plete­ness, and sci­en­tif­ic con­tent of the sub­mis­sion pack­age. FDA review­ers expect clear evi­dence that the pack­ag­ing sys­tem will main­tain steril­i­ty, pro­tect the device through­out its shelf life, and per­form reli­ably under real-world con­di­tions. Any gaps, incon­sis­ten­cies, or unsup­port­ed claims can trig­ger addi­tion­al ques­tions, extend­ing review time­lines nei­ther the cus­tomer nor Fruh could afford.

To meet this chal­lenge, the man­u­fac­tur­er and Fruh worked hand in hand across pack­ag­ing engi­neer­ing, qual­i­fi­ca­tion and val­i­da­tion activ­i­ties (e.g. pack­ag­ing, ster­il­iza­tion, etc.) to ful­fil reg­u­la­to­ry expec­ta­tions and devel­op doc­u­men­ta­tion aligned with FDA review require­ments from the outset.

From an approval per­spec­tive, suc­cess is achieved when review­ers have the infor­ma­tion they need to assess safe­ty and effec­tive­ness with­out request­ing clar­i­fi­ca­tion or addi­tion­al test­ing. That lev­el of con­fi­dence comes from expe­ri­ence with reg­u­la­to­ry scruti­ny, design­ing val­i­da­tion activ­i­ties to with­stand review, and cre­at­ing sub­mis­sion ready doc­u­men­ta­tion. Rather than react­ing to defi­cien­cies after sub­mis­sion, the goal is to build an approval-focused pack­age from the first draft, one that sup­ports a stream­lined review process.

What We Did

To meet an aggres­sive launch time­line, the man­u­fac­tur­er and Fruh joint­ly man­aged the entire pack­ag­ing and ster­il­iza­tion work­stream. Früh pro­vid­ed end-to-end sup­port, includ­ing pro­duc­tion set-up, pack­ag­ing engi­neer­ing, val­i­da­tion and ster­il­iza­tion har­mo­niza­tion for the Class 3 implant, which was offered in both flex­i­ble and rigid pack­ag­ing configurations.

For the man­u­fac­tur­er, how­ev­er, tech­ni­cal exe­cu­tion was only part of the chal­lenge. Reg­u­la­to­ry approval depend­ed not only on com­plet­ing the required test­ing, but on pre­sent­ing the result­ing evi­dence in a way that would with­stand FDA scruti­ny. Every val­i­da­tion report, pro­to­col, and sup­port­ing doc­u­ment need­ed to be com­plete, trace­able, and submission-ready.

To get there, Fruh built the doc­u­men­ta­tion pack­age around how FDA review­ers actu­al­ly work through a sub­mis­sion. Ratio­nale, test meth­ods, results and con­clu­sions were struc­tured to be trace­able end to end, so a review­er could fol­low the log­ic with­out stop­ping to ask for clar­i­fi­ca­tion. Poten­tial gaps were closed before fil­ing rather than after. The result was a com­pre­hen­sive sub­mis­sion pack­age designed to sup­port a smooth review and keep the prod­uct launch on schedule.

Result

The suc­cess­ful FDA sub­mis­sion enabled the man­u­fac­tur­er to suc­cess­ful­ly imple­ment a Local for Local strat­e­gy with­out delays caused by reg­u­la­to­ry find­ings or addi­tion­al infor­ma­tion requests. By secur­ing approval with­in the planned time­line, the com­pa­ny stayed on track with its com­mer­cial objec­tives and con­tin­ued to cre­ate rev­enue as per plan.

The val­ue extend­ed well beyond the sub­mis­sion itself. With a val­i­dat­ed pack­ag­ing and ster­il­iza­tion process in place, the man­u­fac­tur­er gained a more effi­cient and resilient sup­ply chain, includ­ing short­er lead times, local U.S. based sup­port, and greater flex­i­bil­i­ty to respond to chang­ing mar­ket demands. These advan­tages pro­vide a strong foun­da­tion for future prod­uct intro­duc­tions and port­fo­lio expansion.

For the man­u­fac­tur­er, a first-time right sub­mis­sion is more than a reg­u­la­to­ry mile­stone. It reduces risk, pro­tects launch time­lines, and cre­ates the oper­a­tional sta­bil­i­ty need­ed to sup­port long-term growth. When approval is achieved with­out avoid­able delays, the busi­ness can focus on scal­ing pro­duc­tion, serv­ing cus­tomers, and bring­ing the next gen­er­a­tion of prod­ucts to market.